$CSLR
Complete Solaria, Inc. Stock $cslr

$cslr Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000121390024043520 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q2
Revenue	$4.492M	$10.04M	$0.00
YoY Change
Cost Of Revenue	$5.384M	$7.757M	$13.83M
YoY Change	-61.06%
Gross Profit	-$892.0K	$2.283M	$2.850M
YoY Change	-131.3%
Gross Profit Margin	-19.86%	22.74%
Selling, General & Admin	$7.297M	$9.827M
YoY Change
% of Gross Profit		430.44%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$329.0K	$357.0K
YoY Change
% of Gross Profit		15.64%
Operating Expenses	$8.602M	$9.827M	$1.510M
YoY Change	469.67%	506.48%	83.23%
Operating Profit	-$9.494M	-$7.544M	-$1.511M
YoY Change	528.21%	365.58%	83.39%
Interest Expense	$442.0K	$3.568M	$1.410M
YoY Change	-68.65%	26.65%	204.4%
% of Operating Profit
Other Income/Expense, Net	-$4.383M	-$2.043M	-$1.144M
YoY Change	283.06%	-214.1%	-140.15%
Pretax Income	-$13.88M	-$9.587M	-$2.660M
YoY Change	421.69%	-5734.11%	-231.29%
Income Tax	$10.00K	$1.000K
% Of Pretax Income
Net Earnings	-$15.89M	-$9.588M	-$2.655M
YoY Change	498.53%	-5734.86%	-231.07%
Net Earnings / Revenue	-353.83%	-95.5%
Basic Earnings Per Share	-$0.26	-$0.20	-$0.93
Diluted Earnings Per Share	-$0.26	-$0.20	-$0.13
COMMON SHARES
Basic Shares Outstanding	49.10M shares	49.10M shares	25.20M shares
Diluted Shares Outstanding	61.11M shares	49.08M shares	25.20M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$51.84M	$1.786M	$0.00
YoY Change		3656.84%	-100.0%
Cash & Equivalents	$1.839M	$1.786M	$3.251K
Short-Term Investments	$50.00M
Other Short-Term Assets	$7.140M	$5.776M	$0.00
YoY Change			-100.0%
Inventory	$2.033M	$2.773M
Prepaid Expenses
Receivables	$13.00M	$20.94M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$24.02M	$31.27M	$3.251K
YoY Change	738595.79%	65683.22%	-99.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.456M	$4.495M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$118.4M
YoY Change			-65.75%
Other Assets	$198.0K	$198.0K
YoY Change
Total Long-Term Assets	$9.377M	$9.576M	$118.4M
YoY Change	-92.08%	-91.79%	-65.76%
TOTAL ASSETS
Total Short-Term Assets	$24.02M	$31.27M	$3.251K
Total Long-Term Assets	$9.377M	$9.576M	$118.4M
Total Assets	$33.39M	$40.85M	$118.4M
YoY Change	-71.79%	-64.97%	-65.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.00M	$10.52M	$7.000M
YoY Change	57.07%	80.39%	102.07%
Accrued Expenses	$23.23M	$22.22M
YoY Change
Deferred Revenue	$1.248M
YoY Change
Short-Term Debt	$30.38M	$35.80M	$3.500M
YoY Change	767.91%	1190.49%	636.07%
Long-Term Debt Due	$37.15M	$35.84M
YoY Change
Total Short-Term Liabilities	$113.3M	$117.0M	$10.49M
YoY Change	979.85%	1259.87%	166.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.416M	$3.416M	$9.300M
YoY Change	-63.27%	-49.51%	-41.13%
Total Long-Term Liabilities	$3.416M	$3.416M	$9.300M
YoY Change	-63.27%	-49.51%	-41.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$113.3M	$117.0M	$10.49M
Total Long-Term Liabilities	$3.416M	$3.416M	$9.300M
Total Liabilities	$125.4M	$125.9M	$19.79M
YoY Change	533.41%	719.17%	0.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$380.4M	-$364.5M	-$20.03M
YoY Change	1798.83%	1997.52%	6.66%
Common Stock	$288.3M	$7.000K	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$91.97M	-$85.08M	-$19.79M
YoY Change
Total Liabilities & Shareholders Equity	$33.39M	$40.85M	$118.4M
YoY Change	-71.79%	-64.97%	-65.85%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q2
OPERATING ACTIVITIES
Net Income	-$15.89M	-$9.588M	-$2.655M
YoY Change	498.53%	-5734.86%	-231.07%
Depreciation, Depletion And Amortization	$329.0K	$357.0K
YoY Change
Cash From Operating Activities	-$2.691M	-$4.946M	-$340.0K
YoY Change	691.47%	841.41%	-47.89%
INVESTING ACTIVITIES
Capital Expenditures	$347.0K		$30.00K
YoY Change	1056.67%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$400.0K
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	-$347.0K	-$536.0K	-$400.0K
YoY Change	-13.25%	-100.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.034M	$4.726M	700.0K
YoY Change	333.43%	-102.01%	-30.0%
NET CHANGE
Cash From Operating Activities	-2.691M	-$4.946M	-340.0K
Cash From Investing Activities	-347.0K	-$536.0K	-400.0K
Cash From Financing Activities	3.034M	$4.726M	700.0K
Net Change In Cash	-4.000K	-$801.0K	-40.00K
YoY Change	-90.0%	3055.78%	-111.51%
FREE CASH FLOW
Cash From Operating Activities	-$2.691M	-$4.946M	-$340.0K
Capital Expenditures	$347.0K		$30.00K
Free Cash Flow	-$3.038M	-$4.946M	-$370.0K
YoY Change	721.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49077330	shares
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-40117
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	COMPLETE SOLARIA, INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	93-2279786
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	45700 Northport Loop East
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Fremont
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94538
CY2024Q1	dei	City Area Code CityAreaCode	(510)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	270-2507
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	49096537	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1786000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2593000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20939000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26281000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	2773000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	3058000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5776000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5817000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	31274000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	37749000	usd
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3829000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3823000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4495000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4317000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1054000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1235000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	198000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	198000	usd
CY2024Q1	us-gaap	Assets Assets	40850000	usd
CY2023Q4	us-gaap	Assets Assets	47322000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	10521000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13122000	usd
CY2024Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	24893000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	27870000	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	29365000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	28657000	usd
CY2024Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2010000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2423000	usd
CY2024Q1	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	35840000	usd
CY2023Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	33280000	usd
CY2024Q1	cslr	Safe Agreements Current SAFEAgreementsCurrent	5000000	usd
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	9409000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3831000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	117038000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	109183000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3416000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3416000	usd
CY2024Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	3877000	usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	9817000	usd
CY2024Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1055000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1055000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	543000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	664000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	125929000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	124135000	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49096537	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49096537	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49065361	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	49065361	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	279332000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	98000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	143000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-364516000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-354928000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-85079000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-76813000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40850000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47322000	usd
CY2024Q1	us-gaap	Revenues Revenues	10040000	usd
CY2023Q2	us-gaap	Revenues Revenues	16677000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	7757000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	13827000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	2283000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	2850000	usd
CY2024Q1	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	3116000	usd
CY2023Q2	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	5677000	usd
CY2024Q1	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	1618000	usd
CY2023Q2	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	683000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5093000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8913000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	9827000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	15273000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7544000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12423000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	3568000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	3611000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1519000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	317000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2043000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3286000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9587000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15709000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-9588000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-15709000	usd
CY2023Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-7805000	usd
CY2023Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-7805000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-9588000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-23514000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-45000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9633000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23513000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.2
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.62
CY2023Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.31
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.2
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49077330	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25200347	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-76813000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	26000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1341000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-9588000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-45000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-85079000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-50349000	usd
CY2023Q1	cslr	Stock Issued During Period Value Retroactive Application Of Recapitalization StockIssuedDuringPeriodValueRetroactiveApplicationOfRecapitalization	155630000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	55000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1022000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	1000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-23514000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	82845000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-9588000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-23514000	usd
CY2023Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-7805000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-9588000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-15709000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1341000	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	270000	usd
CY2024Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	1008000	usd
CY2023Q2	us-gaap	Paid In Kind Interest PaidInKindInterest	1248000	usd
CY2024Q1	cslr	Non Cash Lease Expense NonCashLeaseExpense	181000	usd
CY2023Q2	cslr	Non Cash Lease Expense NonCashLeaseExpense	248000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	357000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	189000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	62000	usd
CY2023Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2117000	usd
CY2024Q1	cslr	Change In Reserve For Excess And Obsolete Inventory ChangeInReserveForExcessAndObsoleteInventory	-344000	usd
CY2023Q2	cslr	Change In Reserve For Excess And Obsolete Inventory ChangeInReserveForExcessAndObsoleteInventory	791000	usd
CY2024Q1	cslr	Change In Fair Value Of Forward Purchase Agreement Liabilitie ChangeInFairValueOfForwardPurchaseAgreementLiabilitie	5578000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7246000	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-209000	usd
CY2024Q1	cslr	Accretion Of Longterm Debt In Cs Solis AccretionOfLongtermDebtInCSSolis	2560000	usd
CY2023Q2	cslr	Accretion Of Longterm Debt In Cs Solis AccretionOfLongtermDebtInCSSolis	752000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5280000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3197000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-629000	usd
CY2023Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	570000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-41000	usd
CY2023Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1857000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-180000	usd
CY2023Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-86000	usd
CY2023Q2	cslr	Increase Decrease In Warranty Provision Noncurrent IncreaseDecreaseInWarrantyProvisionNoncurrent	100000	usd
CY2023Q2	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	848000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2599000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2132000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1613000	usd
CY2023Q2	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-581000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-413000	usd
CY2023Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-906000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4946000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16116000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-162000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4946000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16278000	usd
CY2023Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	30000	usd
CY2024Q1	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	536000	usd
CY2023Q2	us-gaap	Payments To Acquire Software PaymentsToAcquireSoftware	457000	usd
CY2023Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-536000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-486000	usd
CY2023Q2	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	14102000	usd
CY2024Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	300000	usd
CY2023Q2	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	9603000	usd
CY2023Q2	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	11000000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26000	usd
CY2023Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	55000	usd
CY2024Q1	cslr	Proceeds From Issuance Of Safe Agreements ProceedsFromIssuanceOfSAFEAgreements	5000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4726000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15554000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-45000	usd
CY2023Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-801000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1209000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6416000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8316000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5615000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7107000	usd
CY2023Q2	us-gaap	Interest Paid Net InterestPaidNet	1608000	usd
CY2024Q1	cslr	Purchase Price Per Share PurchasePricePerShare	10
CY2024Q1	us-gaap	Shares Issued SharesIssued	193976	shares
CY2023Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	23256504	shares
CY2023Q1	cslr	Aggregate Amount AggregateAmount	82200000	usd
CY2024Q1	us-gaap	Debt Current DebtCurrent	65.2	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	1800000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2593000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	3829000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	3823000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5615000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6416000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in"><b><i>(b)</i></b></td><td><b><i>Use of Estimates</i></b></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, as well as related disclosure of contingent assets and liabilities. Significant estimates and assumptions made by management include, but are not limited to, the determination of:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">The allocation of the transaction price to identified performance obligations;</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Fair value of warrant liabilities;</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">The reserve methodology for inventory obsolescence;</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">The reserve methodology for product warranty;</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">The reserve methodology for the allowance for credit losses;</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">The fair value of the forward purchase agreements; and</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">The measurement of stock-based compensation.</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent that there are material differences between these estimates and actual results, the Company’s financial condition or operating results will be affected. The Company bases its estimates on past experience and other assumptions that the Company believes are reasonable under the circumstances, and the Company evaluates these estimates on an ongoing basis. The Company has assessed the impact and management is not aware of any specific events or circumstances that required an update to the Company’s estimates and assumptions or materially affected the carrying value of the Company’s assets or liabilities as of the date of issuance of this report. These estimates may change as new events occur and additional information is obtained.</p>
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in"><b><i>(d)</i></b></td><td><b><i>Concentration of Risks </i></b></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company’s cash and cash equivalents are on deposit with major financial institutions. Such deposits may be in excess of insured limits from time to time. The Company believes that the financial institutions that hold the Company’s cash are financially sound, and accordingly, minimum credit risk exists with respect to these balances. The Company has not experienced any losses due to institutional failure or bankruptcy. The Company performs credit evaluations of its customers and generally does not require collateral for sales on credit. The Company reviews accounts receivable balances to determine if any receivables will potentially be uncollectible and includes any amounts that are determined to be uncollectible in the allowance for credit losses. As of March 31, 2024, two customers had an outstanding balance that represented 36% and 19% of the total accounts receivable balance. As of December 31, 2023, two customers had an outstanding balance that represented 38% and 16% of the total accounts receivable balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concentration of customers</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify">For the thirteen-weeks ended March 31, 2024, one customer represented 76% of gross revenues. For the thirteen-weeks ended and April 2, 2023, three customers represented 29%, 23% and 12% of gross revenues.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concentration of suppliers</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the thirteen-weeks ended March 31, 2024, and December 31, 2023, one supplier represented 34% and 40% of the Company’s inventory purchases, respectively.</p>
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	3800000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	3800000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1786000	usd
CY2024Q1	us-gaap	Revenues Revenues	10040000	usd
CY2023Q2	us-gaap	Revenues Revenues	16677000	usd
CY2024Q1	us-gaap	Amount Of Deferred Costs Related To Long Term Contracts AmountOfDeferredCostsRelatedToLongTermContracts	1100000	usd
CY2023Q4	us-gaap	Amount Of Deferred Costs Related To Long Term Contracts AmountOfDeferredCostsRelatedToLongTermContracts	1200000	usd
CY2024Q1	cslr	Deferred Commission DeferredCommission	5100000	usd
CY2023Q4	cslr	Deferred Commission DeferredCommission	4200000	usd
CY2024	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	1300000	usd
CY2023	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	1900000	usd
CY2023	cslr	Direct Offering Costs DirectOfferingCosts	5700000	usd
CY2024Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	45290553	shares
CY2024Q1	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	18291000	usd
CY2023Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	14959000	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2024Q1	us-gaap	Common Stock Convertible Conversion Price Decrease CommonStockConvertibleConversionPriceDecrease	0.59
CY2023	us-gaap	Common Stock Convertible Conversion Price Decrease CommonStockConvertibleConversionPriceDecrease	1.66
CY2024Q1	cslr	Simulation Period SimulationPeriod	P1Y3M18D
CY2023	cslr	Simulation Period SimulationPeriod	P1Y6M18D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.049	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0448	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.12	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.95	pure
CY2024Q1	us-gaap	Fair Value Investments Entities That Calculate Net Asset Value Per Share Planned Sale Investments Not Identified Description FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerSharePlannedSaleInvestmentsNotIdentifiedDescription	The Series D-7 redeemable convertible preferred stock warrants were initially accounted for as liabilities and measured at fair value at the issuance date and as of each subsequent reporting period with changes in the fair value recorded within other income (expense), net in the accompanying unaudited condensed consolidated statements of operations and comprehensive income (loss). As described in Note 12 – Warrants, the redeemable convertible preferred stock warrants were reclassified to additional paid-in capital upon the closing of the Mergers. In October 2023, in connection with the Assignment and Acceptance Agreement as further described in Note 12 – Warrants, these warrants were replaced (“Replacement Warrants”), and the Replacement Warrants are classified as liabilities. Refer to Note 13 – Borrowings and SAFE Agreements.
	us-gaap	Restructuring Reserve Settled Without Cash2 RestructuringReserveSettledWithoutCash2	19700000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	10100000	usd
CY2023Q4	us-gaap	Temporary Equity Share Subscriptions TemporaryEquityShareSubscriptions	31041243	shares
CY2023Q4	cslr	Shares From The Mergers And Pipe Financing SharesFromTheMergersAndPIPEFinancing	19796221	shares
CY2023Q4	cslr	Legacy In Shares LegacyInShares	20034257	shares
CY2023Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	5460075	shares
CY2023Q4	cslr	Shares Of Complete Solaria Common Stock Immediately After Mergers SharesOfCompleteSolariaCommonStockImmediatelyAfterMergers	45290553	shares
CY2024Q1	us-gaap	Professional Fees ProfessionalFees	15800000	usd
CY2024Q1	us-gaap	Interest Costs Incurred InterestCostsIncurred	10600000	usd
CY2023Q4	us-gaap	Cash Cash	5400000	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	cslr	Purchase Percentage PurchasePercentage	0.099	pure
CY2024Q1	cslr	Price On Floor PriceOnFloor	5
CY2024Q1	us-gaap	Fair Value Hedge Assets At Fair Value FairValueHedgeAssetsAtFairValue	100000	usd
CY2024Q1	us-gaap	Other General Expense OtherGeneralExpense	5600000	usd
CY2024Q1	us-gaap	Other Liabilities OtherLiabilities	9400000	usd
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	3800000	usd
CY2023Q4	cslr	Reset Floor Price ResetFloorPrice	3
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	10000000	usd
CY2024Q1	cslr	Prepaid Sales Commissions PrepaidSalesCommissions	5098000	usd
CY2023Q4	cslr	Prepaid Sales Commissions PrepaidSalesCommissions	4185000	usd
CY2023Q4	us-gaap	Prepaid Rent PrepaidRent	616000	usd
CY2024Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	678000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1016000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5776000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5817000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8464000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7928000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	3969000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	3611000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	4495000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	4317000	usd
CY2024Q1	us-gaap	Utilities Operating Expense Depreciation And Amortization UtilitiesOperatingExpenseDepreciationAndAmortization	400000	usd
CY2023Q2	us-gaap	Utilities Operating Expense Depreciation And Amortization UtilitiesOperatingExpenseDepreciationAndAmortization	200000	usd
CY2024Q1	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	3715000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current And Noncurrent AccruedEmployeeBenefitsCurrentAndNoncurrent	3969000	usd
CY2024Q1	cslr	Accrued Customer Deposits AccruedCustomerDeposits	296000	usd
CY2023Q4	cslr	Accrued Customer Deposits AccruedCustomerDeposits	544000	usd
CY2024Q1	cslr	Accrued Uninvoiced Contract Costs AccruedUninvoicedContractCosts	80000	usd
CY2023Q4	cslr	Accrued Uninvoiced Contract Costs AccruedUninvoicedContractCosts	671000	usd
CY2024Q1	cslr	Accrued Term Loan And Revolving Loan Amendment And Final Payment Fees AccruedTermLoanAndRevolvingLoanAmendmentAndFinalPaymentFees	2400000	usd
CY2023Q4	cslr	Accrued Term Loan And Revolving Loan Amendment And Final Payment Fees AccruedTermLoanAndRevolvingLoanAmendmentAndFinalPaymentFees	2400000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7700000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7700000	usd
CY2024Q1	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	930000	usd
CY2023Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	931000	usd
CY2024Q1	cslr	Accrued Rebate And Credits AccruedRebateAndCredits	32000	usd
CY2023Q4	cslr	Accrued Rebate And Credits AccruedRebateAndCredits	677000	usd
CY2024Q1	cslr	Accured Operating Lease Liabilities Current AccuredOperatingLeaseLiabilitiesCurrent	548000	usd
CY2023Q4	cslr	Accured Operating Lease Liabilities Current AccuredOperatingLeaseLiabilitiesCurrent	607000	usd
CY2024Q1	cslr	Accrued Warranty Current AccruedWarrantyCurrent	1449000	usd
CY2023Q4	cslr	Accrued Warranty Current AccruedWarrantyCurrent	1433000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7743000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8938000	usd
CY2024Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	24893000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	27870000	usd
CY2024Q1	cslr	Proceeds From Issuance Of Redeemable Convertible Preferred Stock1 ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock1	-1305000	usd
CY2023Q2	cslr	Proceeds From Issuance Of Redeemable Convertible Preferred Stock1 ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock1	-209000	usd
CY2024Q1	cslr	Change In Fair Value Of Carlyle Warrants ChangeInFairValueOfCarlyleWarrants	6429000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	489000	usd
CY2024Q1	cslr	Change In Fair Value Of Forward Purchase Agreement Liabilities ChangeInFairValueOfForwardPurchaseAgreementLiabilities	5578000	usd
CY2024Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-148000	usd
CY2023Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	108000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1519000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	317000	usd
CY2023Q4	us-gaap	Share Price SharePrice	1.36
CY2023	cslr	Aggregate Amount Of Purchase Price AggregateAmountOfPurchasePrice	4999999.2	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	27637266	shares
CY2024Q1	cslr	Stock Issued During Employee Stock Purchase Plan StockIssuedDuringEmployeeStockPurchasePlan	2628996	shares
CY2024Q1	cslr	Stock Options And Restricted Stock Units Issued And Outstanding StockOptionsAndRestrictedStockUnitsIssuedAndOutstanding	11436369	shares
CY2024Q1	cslr	Stock Options And Restricted Stock Units Authorized For Future Issuance StockOptionsAndRestrictedStockUnitsAuthorizedForFutureIssuance	3850462	shares
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	45553093	shares
CY2024Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3882000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	11127000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2190604	shares
CY2024Q1	us-gaap	Financial Guarantee Insurance Contracts Claim Liability Weighted Average Risk Free Discount Rate FinancialGuaranteeInsuranceContractsClaimLiabilityWeightedAverageRiskFreeDiscountRate	0.019	pure
CY2024Q1	cslr	Common Stock Issued And Outstanding Percentage CommonStockIssuedAndOutstandingPercentage	0.02795	pure
CY2024Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	350000	shares
CY2024Q1	cslr	Warrant Vesting Shares WarrantVestingShares	350000	shares
CY2024Q1	cslr	Common Stock Trading Days CommonStockTradingDays	P10D
CY2024Q1	cslr	Warrant Vesting Agreement Exercisable Shares WarrantVestingAgreementExercisableShares	150000	shares
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	9500000	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	8625000	shares
CY2024Q1	us-gaap	Other Noncash Income Tax Expense OtherNoncashIncomeTaxExpense	20000.00	usd
CY2024Q1	us-gaap	Notes And Loans Payable NotesAndLoansPayable	29365000	usd
CY2023Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	28657000	usd
CY2024Q1	us-gaap	Convertible Debt ConvertibleDebt	35840000	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	33280000	usd
CY2024Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	65205000	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	61937000	usd
CY2024Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	65205000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	61937000	usd
CY2024Q1	us-gaap	Time Deposits At Carrying Value TimeDepositsAtCarryingValue	11400000	usd
CY2024Q1	us-gaap	Interest Expense Borrowings InterestExpenseBorrowings	300000	usd
CY2023Q2	us-gaap	Interest Expense Borrowings InterestExpenseBorrowings	300000	usd
CY2023	cslr	Prime Rate Plus PrimeRatePlus	0.045	pure
CY2023Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	1900000	usd
CY2023Q4	us-gaap	Investment Sold Not Yet Purchased Balance Principal Amount InvestmentSoldNotYetPurchasedBalancePrincipalAmount	5100000	usd
CY2022	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.70	pure
CY2022	us-gaap	Repayments Of Longterm Loans From Vendors RepaymentsOfLongtermLoansFromVendors	10000000	usd
CY2022Q4	us-gaap	Deposits Paid For Securities Borrowed At Carrying Value DepositsPaidForSecuritiesBorrowedAtCarryingValue	20000000	usd
CY2024Q1	cslr	Outstanding Net Debt Amount OutstandingNetDebtAmount	12700000	usd
CY2024Q1	us-gaap	Financing Receivable Unamortized Loan Fee Cost FinancingReceivableUnamortizedLoanFeeCost	5000000	usd
CY2023	cslr	Outstanding Net Debt Amount OutstandingNetDebtAmount	12200000	usd
CY2023Q4	us-gaap	Financing Receivable Unamortized Loan Fee Cost FinancingReceivableUnamortizedLoanFeeCost	4500000	usd
CY2024Q1	cslr	Recognized Interest Expense RecognizedInterestExpense	500000	usd
CY2023Q2	cslr	Recognized Interest Expense RecognizedInterestExpense	1700000	usd
CY2023Q3	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	500000	usd
CY2024Q1	us-gaap	Investment Owned Underlying Face Amount At Market Value InvestmentOwnedUnderlyingFaceAmountAtMarketValue	300000	usd
CY2024Q1	us-gaap	Preferred Units Contributed Capital PreferredUnitsContributedCapital	25600000	usd
CY2024Q1	cslr	Investment Dividend Payable Percentage InvestmentDividendPayablePercentage	0.25	pure
CY2024Q1	cslr	Warrant To Purchase Shares WarrantToPurchaseShares	5978960	shares
CY2024Q1	cslr	Exercisable Shares ExercisableShares	4132513	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	139000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	215000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	4536233	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	4.38
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y9M10D
CY2024Q1	cslr	Investment Description InvestmentDescription	The Carlyle Debt Modification Agreement accelerates the redemption date of the investment, which was previously February 14, 2025 and is now March 31, 2024 subsequent to the modification. The acceleration of the redemption date of the investment, resulted in the total redemption amount to be 1.3 times the principal at December 31, 2023. The redemption amount will increase to 1.4 times the original investment at March 31, 2024. Additionally, as part of the amendment, the parties entered into an amended and restated warrant agreement. As part of the Carlyle Warrant Amendment, Complete Solaria issued Carlyle a warrant to purchase up to 2,745,879 shares of Complete Solaria Common Stock at a price per share of $0.01, which is inclusive of the outstanding warrant to purchase 1,995,879 shares at the time of modification. The warrant, which expires on July 18, 2030, provides Carlyle with the right to purchase shares of Complete Solaria Common Stock based on (a) the greater of (i) 1,995,879 shares and (ii) the number of shares equal to 2.795% of Complete Solaria’s issued and outstanding shares of common stock, on a fully-diluted basis; plus (b) on and after the date that is ten (10) days after the date of the agreement, an additional 350,000 shares; plus (c) on and after the date that is thirty (30) days after the date of the agreement, if the original investment amount has not been repaid, an additional 150,000 shares; plus (d) on and after the date that is ninety (90) days after the date of the agreement, if the original investment amount has not been repaid, an additional 250,000 shares, in each case, of Complete Solaria Common Stock at a price of $0.01 per share. The warrants are classified as liabilities under ASC 815 and are recorded within warrant liability on the Company’s unaudited condensed consolidated statements of operations and comprehensive loss.
CY2023Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	10300000	usd
CY2024Q1	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	28400000	usd
CY2024Q1	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	35800000	usd
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	35800000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	33300000	usd
CY2024Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
CY2024Q1	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	35800000	usd
CY2024Q1	us-gaap	Dividends Cash DividendsCash	1500000	usd
CY2024Q1	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	1431297
CY2024Q1	cslr	Closing Price Per Share ClosingPricePerShare	1.31
CY2024Q1	cslr	Purchaser Investing PurchaserInvesting	3500000	usd
CY2024Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	3500000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	3707627	shares
CY2024Q1	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	0.80	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11716646	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.48
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M10D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2756000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	31176	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.83
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	307198	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.86
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11378272	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.5
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	215000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	11378272	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.5
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y3M
CY2024Q1	cslr	Market Fair Value Offering Proceeds Percentage MarketFairValueOfferingProceedsPercentage	0.85	pure
CY2024Q1	us-gaap	Employee Stock Ownership Plan Esop Number Of Committed To Be Released Shares EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares	2628996	shares
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	4849000	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	3981000	usd
CY2024Q1	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	265000	usd
CY2023	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	2968000	usd
CY2024Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	250000	usd
CY2023	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	2100000	usd
CY2024Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	4864000	usd
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	4849000	usd
CY2024Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1448000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	1433000	usd
CY2024Q1	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	3416000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	3416000	usd
CY2023	us-gaap	Lease Cost LeaseCost	7900000	usd
CY2023Q1	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	26400000	usd
CY2023Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	220000000	usd
CY2021Q3	us-gaap	Asset Recovery Damaged Property Costs Noncurrent AssetRecoveryDamagedPropertyCostsNoncurrent	6900000	usd
CY2024Q1	cslr	Inclusive Amounts Of Indemnity InclusiveAmountsOfIndemnity	6900000	usd
CY2024Q1	cslr	Attorneys Fees Expenses And Prejudgement Interest AttorneysFeesExpensesAndPrejudgementInterest	2670000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	6900000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	2670000	usd
CY2023Q3	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	6000000	usd
CY2023Q3	us-gaap	Subadvisory Fees For Mutual Funds SubadvisoryFeesForMutualFunds	6000000	usd
CY2024Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	3500000	usd
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	3800000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	3800000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-9588000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-15709000	usd
CY2023Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-7805000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-9588000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-23514000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49077330	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25200347	shares
CY2024Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.2
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.62
CY2023Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.31
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.2
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	34460924	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12191086	shares
	cslr	Fair Value Acquisition FairValueAcquisition	6700000	usd
	us-gaap	Related Party Transaction Rate RelatedPartyTransactionRate	0.05	pure
CY2020	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	12100000	usd
CY2022Q1	cslr	Recognized A Liability RecognizedALiability	7900000	usd
CY2022Q1	us-gaap	Other Receivables OtherReceivables	4700000	usd
CY2023	us-gaap	Related Party Tax Expense Effect Of Change In Allocation Methodology RelatedPartyTaxExpenseEffectOfChangeInAllocationMethodology	200000	usd
CY2024Q1	us-gaap	Related Party Tax Expense Effect Of Change In Allocation Methodology RelatedPartyTaxExpenseEffectOfChangeInAllocationMethodology	300000	usd
CY2024Q1	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	5000000	usd
CY2024Q1	us-gaap	Common Stock Convertible Conversion Price Increase CommonStockConvertibleConversionPriceIncrease	0.36
CY2024Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1
CY2024Q1	us-gaap	Net Asset Value Per Share NetAssetValuePerShare	1
CY2024Q2	cslr	Purchaser Investing PurchaserInvesting	50000000	usd
CY2024Q1	cslr	Received Amount ReceivedAmount	50000000	usd
CY2024Q2	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	0.62
CY2024Q2	cslr	Cash Payment CashPayment	3750000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	277965000	usd
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity		usd
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25200347	shares
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity		usd
CY2023Q2	cslr	Change In Fair Value Of Forward Purchase Agreement Liabilitie ChangeInFairValueOfForwardPurchaseAgreementLiabilitie		usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets		usd
CY2024Q1	cslr	Increase Decrease In Warranty Provision Noncurrent IncreaseDecreaseInWarrantyProvisionNoncurrent		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations		usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2024Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2024Q1	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable		usd
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023Q2	cslr	Proceeds From Issuance Of Safe Agreements ProceedsFromIssuanceOfSAFEAgreements		usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q2	cslr	Change In Fair Value Of Carlyle Warrants ChangeInFairValueOfCarlyleWarrants		usd
CY2023Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2023Q2	cslr	Change In Fair Value Of Forward Purchase Agreement Liabilities ChangeInFairValueOfForwardPurchaseAgreementLiabilities		usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments		usd
CY2024Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Lease Cost LeaseCost		usd
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax		usd
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25200347	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49077330	shares
CY2024Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.20
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.62
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2023Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.31
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2024Q1	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare
CY2023Q2	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001838987

Files In Submission

Name	View Source	Status
cslr-20240331_cal.xml	Edgar Link	unprocessable
0001213900-24-043520-index-headers.html	Edgar Link	pending
0001213900-24-043520-index.html	Edgar Link	pending
0001213900-24-043520.txt	Edgar Link	pending
0001213900-24-043520-xbrl.zip	Edgar Link	pending
cslr-20240331.xsd	Edgar Link	pending
ea0205629-10q_complete.htm	Edgar Link	pending
ea020562901ex31-1_complete.htm	Edgar Link	pending
ea020562901ex31-2_complete.htm	Edgar Link	pending
ea020562901ex32-1_complete.htm	Edgar Link	pending
ea020562901ex32-2_complete.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
cslr-20240331_def.xml	Edgar Link	unprocessable
cslr-20240331_lab.xml	Edgar Link	unprocessable
cslr-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0205629-10q_complete_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSLR
Complete Solaria, Inc. Stock $cslr

2024 Q2 Form 10-Q Financial Statement

#000121390024043520 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSLR Complete Solaria, Inc. Stock $cslr

2024 Q2 Form 10-Q Financial Statement

#000121390024043520 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSLR
Complete Solaria, Inc. Stock $cslr